Latest Research
12 Articles
Six Researchers Shaping What Comes Next
Meet the six young researchers whose attendance at the AACR pancreatic cancer conference was sponsored by Let’s Win.
The Latest Research: The 2026 AACR Conference on Pancreatic Cancer
At the 2026 AACR Pancreatic Cancer conference, researchers reported on daraxonrasib and other KRAS targeting drugs.
Confirming the Link Between New-Onset Diabetes and Pancreatic Cancer
Dr. Suresh Chari outlines interim study results that confirm the link between new-onset diabetes and pancreatic cancer.
A New Approach to MEK Inhibition for First-Line Treatment
Dr. Eileen O’Reilly outlines a phase III trial of a targeted therapy for patients with metastatic pancreatic cancer.
Could AI Help Detect the Pancreatic Cancers We Usually Miss?
Dr. Ajit Goenka is leading a team at the Mayo Clinic that is exploring how AI can be used to find random pancreatic cancer.
The Risk of a Dilated Pancreatic Duct
Dr. Mimi Canto and the team at Johns Hopkins have identified a dilated pancreatic duct as a risk factor for pancreatic cancer.
Tackling KRAS G12D
Dr. Leon Pappas explains the workings of the new KRAS G12D inhibitor, now in phase I/II clinical trials around the US and Australia.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
2026 AACR Annual Meeting Gives Hope for the Future
Research highlights from the 2026 AACR Meeting featured advances in pancreatic cancer treatment, focusing on KRAS and vaccines,